Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

Recruiting now · Phase 2

Conditions studied: Castrate Resistance Prostate Cancer, OligoProgressive Metastatic Disease

In brief

This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).

Key facts

Study ID

NCT06927635

Run by

University Health Network, Toronto

People needed

75

Starts

2025-07-08

Expected to finish

2030-06-01

Last updated by the study team

2026-07-07

Who can join

Age: 18 and older, up to 100. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Age >18 years
• Able to provide informed consent
• Histologic diagnosis of prostate adenocarcinoma
• Castrate Resistance Prostate Cancer
• Radiographic evidence of <10 sites of extra-cranial OP metastatic lesions
• Receiving any line of ST for >3 months
• All sites of OP disease are amenable to and can be safely treated with SBRT
• ECOG performance status 0-3

You may not qualify if…

• Evidence of spinal cord compression
• Contraindication to radiotherapy

Where it is running

• Princess Margaret Cancer Center — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.